Leerink Partnrs Expects Stronger Earnings for XOMA Royalty

XOMA Royalty Corporation (NASDAQ:XOMA) – Equities research analysts at Leerink Partnrs increased their FY2029 earnings estimates for XOMA Royalty in a report released on Wednesday, November 12th. Leerink Partnrs analyst D. Risinger now expects that the biotechnology company will post earnings per share of $6.15 for the year, up from their previous forecast of $6.04. The consensus estimate for XOMA Royalty’s current full-year earnings is ($1.41) per share.

XOMA Royalty (NASDAQ:XOMA) last posted its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.33). The company had revenue of $9.35 million for the quarter, compared to analysts’ expectations of $11.47 million. XOMA Royalty had a positive return on equity of 2.63% and a negative net margin of 27.57%.

Several other equities analysts have also issued reports on XOMA. Zacks Research lowered XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of XOMA Royalty in a report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of XOMA Royalty from a “hold” rating to a “buy” rating in a research report on Monday, August 11th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, XOMA Royalty has a consensus rating of “Hold” and a consensus target price of $69.50.

XOMA Royalty Stock Down 1.3%

Shares of XOMA traded down $0.43 during trading hours on Friday, hitting $31.81. The company had a trading volume of 16,731 shares, compared to its average volume of 45,857. The company has a current ratio of 4.88, a quick ratio of 4.88 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $384.47 million, a PE ratio of -20.57 and a beta of 1.12. XOMA Royalty has a one year low of $18.35 and a one year high of $39.92. The company’s fifty day moving average price is $35.85 and its two-hundred day moving average price is $30.09.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in XOMA. Nuveen LLC purchased a new stake in shares of XOMA Royalty during the first quarter valued at $286,000. Stonepine Capital Management LLC grew its stake in XOMA Royalty by 3.3% during the 1st quarter. Stonepine Capital Management LLC now owns 129,813 shares of the biotechnology company’s stock valued at $2,587,000 after purchasing an additional 4,113 shares during the last quarter. CM Management LLC increased its holdings in shares of XOMA Royalty by 16.4% in the first quarter. CM Management LLC now owns 64,000 shares of the biotechnology company’s stock valued at $1,276,000 after purchasing an additional 9,000 shares during the period. Deutsche Bank AG raised its stake in shares of XOMA Royalty by 5,087.9% in the first quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 6,309 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of XOMA Royalty during the second quarter worth about $370,000. Hedge funds and other institutional investors own 95.92% of the company’s stock.

Insider Activity at XOMA Royalty

In related news, CFO Thomas M. Burns sold 4,330 shares of XOMA Royalty stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $35.99, for a total value of $155,836.70. Following the completion of the sale, the chief financial officer directly owned 30,079 shares in the company, valued at $1,082,543.21. This trade represents a 12.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 9.10% of the stock is owned by insiders.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.